EKSO BIONICS HOLDING (OTCBB:EKSO) has announced the launch of an updated version of robotic gait therapy software to go with its exo-skeletons. The software will be first made available in Europe and is expected to be launched the DMGP meeting, due to be held in Kassel, Germany. The meeting brings together specialists to address the needs of quality, comprehensive and successful treatment of paraplegic patients.
The update includes enhanced adaptive assistance software, a suite for early mobilization activities and an advanced mode for patients moving towards community ambulation. The announcement was made during Rehab Week 2015, with the company revealing that the package would also support Functional Electric Stimulation. This has been done to help centers operating under research protocols to partner with Ekso for research based therapies. The new software suite would help cater to the needs of a larger patient population, to accelerate their recovery process.
Additionally, the program is editable, which means that the pace of the program can be altered as per the varying needs of every patient. It is anticipated that the program would launch in Europe by the end of 2015. The company has also filed an S-3 with the SEC, which enables Ekso to issue various types of securities, as long as the total compensation amounts to $75 million. Nathan Harding, CEO of Ekso, stated that the option would allow the company to gain financial flexibility, so the company can quickly meet its growth objectives.
EKSO is slowly making a comeback in the stock market, after a number of red flags around the company were identified by analysts. Since the shots were fired, the company has been going downhill, with little chance of recovering. However, the company tends to keep away from any promotions to help increase shareholder value.
EKSO BIONICS HOLDING (OTCBB:EKSO) traded a total of 1.03 million shares during the June 25 session to close at a share price of $1.10, after declining by 7.17% during the session.